Please login to the form below

Not currently logged in
Email:
Password:

motor neurone disease

This page shows the latest motor neurone disease news and features for those working in and with pharma, biotech and healthcare.

AB Science claims first with motor neurone disease therapy

AB Science claims first with motor neurone disease therapy

AB Science claims first with motor neurone disease therapy. ALS patients on masitnib lived longer without their disease progressing. ... French biotech AB Science is celebrating after a pivotal trial of its lead drug masitinib for motor neurone disease

Latest news

  • PatientsLikeMe launches 'virtual trial' in ALS PatientsLikeMe launches 'virtual trial' in ALS

    PatientsLikeMe has started a small-scale 'virtual trial' to evaluate the potential of a peptide to reverse the symptoms of degenerative motor disorder ALS. ... The online community is working with The Duke ALS Clinical in the US on the study, which will

  • FDA grants orphan drug status to Treeway's ALS treatment FDA grants orphan drug status to Treeway's ALS treatment

    ALS, which is commonly known as Lou Gehrig's disease in the US and as motor neurone disease in certain other countries, causes muscle weakness, disability and eventually death. ... The disease received a major boost in awareness last year due to the ALS

  • Charity coalition pledges millions for brain disease research Charity coalition pledges millions for brain disease research

    Charity coalition pledges millions for brain disease research. Will invest £30m developing candidates for neurodegenerative conditions. ... The funding will focus on neurodegenerative conditions, such as dementia, motor neurone disease and Parkinson's

  • Pharma takes the ALS Ice Bucket Challenge Pharma takes the ALS Ice Bucket Challenge

    weeks. Evotec's motor neuron researchers performed the ice bucket challenge outside their headquarters in Hamburg after challenging CEO Dr Werner Lanthaler and CSO Cord Dohrmann, who later accepted. ... ALS, which is the most common type of motor neurone

  • Biogen Idec signs brain research deal with Edinburgh University Biogen Idec signs brain research deal with Edinburgh University

    Biogen Idec signs brain research deal with Edinburgh University. Will identify potential treatments for multiple sclerosis and motor neurone disease. ... US biotech Biogen Idec is to research potential new treatments for the neurodegenerative conditions

More from news
Approximately 5 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    This has a knock-on effect for research around rare disease types specifically. ... In fact, this has helped our team of scientists at BenevolentBio establish a set of hypotheses for drug candidates for Amyotrophic Lateral Sclerosis (ALS), a form of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Biogen Idec names ALS unit head Biogen Idec names ALS unit head

    ALS, which is commonly known as Lou Gehrig's disease in the US and as motor neurone disease in certain other countries, has received a boost in awareness in recent weeks

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics